61 results on '"Giralt, Sergio"'
Search Results
2. Adenovirus Viral Kinetics and Mortality in Ex Vivo T Cell-Depleted Hematopoietic Cell Transplant Recipients With Adenovirus Infection From a Single Center.
- Author
-
Lee, Yeon Joo, Fang, Jiaqi, Zavras, Phaedon D, Prockop, Susan E, Boulad, Farid, Tamari, Roni, Perales, Miguel Angel, Papadopoulos, Esperanza B, Jakubowski, Ann A, Giralt, Sergio A, and Papanicolaou, Genovefa A
- Subjects
ADENOVIRUS diseases ,ADENOVIRUSES ,LYMPHOCYTE count ,ANALYTICAL mechanics ,TRANSPLANTATION of organs, tissues, etc. ,MORTALITY ,RESEARCH ,GRAFT versus host disease ,HOMOGRAFTS ,VIRUSES ,VIRAL load ,RESEARCH methodology ,IMMUNOSUPPRESSION ,DNA virus diseases ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,VIREMIA ,BLOOD diseases ,SURVIVAL analysis (Biometry) ,RESEARCH funding ,T cells ,HEMATOPOIETIC stem cell transplantation ,IMMUNOSUPPRESSIVE agents - Abstract
Background: We report on predictors of adenovirus (ADV) viremia and correlation of ADV viral kinetics with mortality in ex vivo T-cell depleted (TCD) hematopoietic cell transplant (HCT).Methods: T cell-depleted HCT recipients from January 1, 2012 through September 30, 2018 were prospectively monitored for ADV in the plasma through Day (D) +100 posttransplant or for 16 weeks after the onset of ADV viremia. Adenovirus viremia was defined as ≥2 consecutive viral loads (VLs) ≥1000 copies/mL through D +100. Time-averaged area under the curve (AAUC) or peak ADV VL through 16 weeks after onset of ADV viremia were explored as predictors of mortality in Cox models.Results: Of 586 patients (adult 81.7%), 51 (8.7%) developed ADV viremia by D +100. Age <18 years, recipient cytomegalovirus seropositivity, absolute lymphocyte count <300 cells/µL at D +30, and acute graft-versus-host disease were predictors of ADV viremia in multivariate models. Fifteen (29%) patients with ADV viremia died by D +180; 8 of 15 (53%) died from ADV. Peak ADV VL (hazard ratio [HR], 2.25; 95% confidence interval [CI], 1.52-3.33) and increasing AAUC (HR, 2.95; 95% CI, 1.83-4.75) correlated with mortality at D +180.Conclusions: In TCD HCT, peak ADV VL and ADV AAUC correlated with mortality at D +180. Our data support the potential utility of ADV viral kinetics as endpoints in clinical trials of ADV therapies. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
3. Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.
- Author
-
Ceberio, Izaskun, Devlin, Sean M., Sauter, Craig, Barker, Juliet N., Castro-Malaspina, Hugo, Giralt, Sergio, Ponce, Doris M., Lechner, Lauren, Maloy, Molly A., Goldberg, Jenna D., and Perales, Miguel-Angel
- Subjects
RAPAMYCIN ,TACROLIMUS ,METHOTREXATE ,GRAFT versus host disease ,HEMATOPOIETIC stem cell transplantation ,LYMPHOID tissue ,CANCER ,THERAPEUTICS - Abstract
Encouraging results have been reported with sirolimus, tacrolimus and low-dose methotrexate after non-myeloablative allogeneic hematopoietic cell transplant. We conducted a retrospective analysis of 71 patients with lymphoid malignancies treated with this prophylaxis regimen after non-myeloablative or reduced intensity allogeneic hematopoietic cell transplant. Grafts were human leukocyte antigen (HLA)-matched related in 29 (41%), matched unrelated in 36 (51%) and 9/10 HLA-matched unrelated in six (8%) patients. The regimen was well tolerated and over 90% of patients completed the planned treatment. The cumulative incidences of 1-year grade B-D and C-D acute graft-versus-host disease (GVHD) were 0.28 (95% confidence interval [CI], 0.18-0.39) and 0.07 (95% CI, 0.03-0.15), respectively, and of 1- and 2-year chronic GVHD (National Institutes of Health criteria) in 70 evaluable patients were 0.15 (95% CI, 0.08-0.24) and 0.33 (95% CI, 0.22-0.44), respectively. The median day of onset of acute GVHD was 123 days (range, 17-268 days). Peri-transplant rituximab or anti-thymocyte globulin did not affect GVHD. The cumulative incidence of 1-year non-relapse mortality and relapse were 4% and 20%, respectively. With a median follow-up of 3.5 (range: 0.18-5.1) years, overall survival and progression-free survival at 2 years were 82% and 66%, respectively. This GVHD regimen results in a low incidence and severity of acute and chronic GVHD after reduced intensity and non-myeloablative allogeneic hematopoietic cell transplant for lymphoid malignancies. The study also highlights the incidence of late onset acute GVHD in non-myeloablative/reduced intensity conditioning, and the contribution of the new GVHD staging system that more accurately reflects clinical outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
4. A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignancies.
- Author
-
Sauter, Craig S., Chou, Joanne F., Papadopoulos, Esperanza B., Perales, Miguel-Angel, Jakubowski, Ann A., Young, James W., Scordo, Michael, Giralt, Sergio, and Castro-Malaspina, Hugo
- Subjects
ALEMTUZUMAB ,STEM cell transplantation research ,GRAFT versus host disease ,MELPHALAN ,DISEASE progression - Abstract
Reduced-intensity conditioning (RIC) regimens for allogeneic stem cell transplant (allo-SCT) have used alemtuzumab to abrogate the risk of graft-versus-host disease (GVHD). Thirty-eight patients with advanced lymphoma underwent a prospective phase II study of melphalan, fludarabine and alemtuzumab containing RIC allo-SCT from 20 matched related and 18 unrelated donors with cyclosporine-A as GVHD prophylaxis. The cumulative incidence of grade II-IV acute GVHD at 3 months was 10.5% and three evaluable patients experienced chronic GVHD. Progression-free (PFS) and overall (OS) survival at 5 years was 25% (95% confidence interval [CI]: 13-40%) and 44% (95% CI: 28-59%), respectively. Previous high-dose therapy and autologous stem cell transplant (HDT-ASCT) and elevated lactate dehydrogenase (LDH) at the time of allo-SCT resulted in inferior OS. Within this cohort of patients with high-risk lymphoma, alemtuzumab containing RIC resulted in a low risk of GVHD and a high incidence of progression of disease, especially in those with poor-risk features defined by elevated LDH pre-allo-SCT and previous HDT-ASCT. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
5. Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant.
- Author
-
Goldberg, Jenna D., Chou, Joanne F., Horwitz, Steven, Teruya-Feldstein, Julie, Barker, Juliet N, Boulad, Farid, Castro-Malaspina, Hugo, Giralt, Sergio, Jakubowski, Ann A., Koehne, Guenther, van den Brink, Marcel R. M., Young, James W., Zhang, Zhigang, Papadopoulos, Esperanza B., and Perales, Miguel-Angel
- Subjects
T-cell lymphoma ,GRAFT versus host disease ,HEMATOPOIETIC stem cell transplantation ,DISEASE incidence ,LEUCOCYTES - Abstract
Peripheral T-cell non-Hodgkin lymphomas (T-NHL) are rare diseases, with a worse prognosis compared to their B-cell counterparts. Allogeneic hematopoietic stem cell transplant may have a role in the treatment of relapsed/refractory disease or high-risk histologies in the upfront setting. However, there is limited information on the efficacy of allogeneic transplant for these diseases, as well as what factors may predict outcomes. We therefore performed a retrospective study of 34 patients who received an allogeneic transplant for the treatment of T-NHL at a single center between 1 January 1992 and 31 December 2009. The median follow-up for survivors was 45 months (range 9-160 months). The 2-year overall survival (OS) was 0.61 (95% confidence interval [CI]: 0.43-0.75) with a plateau at 28 months. Ki-67 expression ≤ 25% was predictive of improved OS ( p < 0.01), and transplant in complete remission was predictive of a decreased cumulative incidence of events ( p = 0.04). Three patients received a donor leukocyte infusion, and two patients demonstrated a response, supporting a graft-versus-lymphoma effect. These data demonstrate that allogeneic transplant is a viable option for the treatment of T-NHL and merits prospective evaluation. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
6. Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant.
- Author
-
Bashir, Qaiser, Munsell, Mark F., Giralt, Sergio, de Padua Silva, Leandro, Sharma, Manish, Couriel, Daniel, Chiattone, Alexandre, Popat, Uday, Qazilbash, Muzaffar H., Fernandez-Vina, Marcelo, Champlin, Richard E., and de Lima, Marcos J.
- Subjects
BONE marrow transplant complications ,GRAFT versus host disease ,PATIENTS ,MORTALITY ,DEMOGRAPHY - Abstract
The optimal dose and schedule of thymoglobulin (ATG) for graft-versus-host disease prevention (GVHD) is unknown. We compared two doses of ATG (4.5 mg/kg and 7.5 mg/kg) in a Bayesian adaptively randomized fashion, and assessed whether ATG levels measured on days 0, 7, 14 and 28 were associated with clinical outcomes. Treatment success was defined as the patient being alive, engrafted, in remission and without acute GVHD at day 100. Twenty patients received ATG 4.5 mg/kg ( n == 15) or 7.5 mg/kg ( n == 5) with reduced-intensity conditioning followed by unrelated donor hematopoietic cell transplant. The first 10 patients were fairly randomized, but the next 10 patients were adaptively randomized to the arm with higher success rate (4.5 mg/kg arm in this trial). The posterior mean treatment success rates for the ATG 4.5 mg/kg and ATG 7.5 mg/kg arms were 0.73 and 0.45, respectively. The posterior probability that the success rate was greater in the 4.5 mg/kg arm than in the 7.5 mg/kg arm was 0.93. There was no difference in the overall survival (p == 0.607), relapse-free survival ( p == 0.607), treatment-related mortality ( p == 0.131) or incidence of acute ( p == 0.303) or chronic GVHD ( p == 0.999) between the two doses. ATG levels were not associated with clinical outcomes. Thus, our results favor the use of ATG 4.5 mg/kg over ATG 7.5 mg/kg in patients undergoing unrelated donor hematopoietic cell transplant with reduced-intensity conditioning regimens. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
7. Low-Dose Azacitidine After Allogeneic Stem Cell Transplantation for Acute Leukemia.
- Author
-
Jabbour, Elias, Giralt, Sergio, Kantarjian, Hagop, Garcia-Manero, Guillermo, Jagasia, Madan, Kebriaei, Partow, de Padua, Leandro, Shpall, Elizabeth J., Champlin, Richard, and de Lima, Marcos
- Subjects
- *
TRANSPLANTATION of organs, tissues, etc. , *ACUTE leukemia , *GRAFT versus host disease , *IMMUNOLOGICAL tolerance , *LEUKEMIA , *CANCER chemotherapy , *PHYSIOLOGY , *LEUKEMIA treatment - Abstract
The article discusses the efficacy of hypomethylating agent 5-azacitidine in treating patients with acute leukemia. The authors claim that low doses of 5-azacitidine may maximize the graft-versus-leukemia effect and may be tolerated well after allogeneic transplantation (HSCT). They add that it may induce durable remissions for patients who develop disease recurrence after HSCT.
- Published
- 2009
- Full Text
- View/download PDF
8. Increased Bone Marrow Iron Stores Is an Independent Risk Factor for Invasive Aspergillosis in Patients With High-Risk Hematologic Malignancies and Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.
- Author
-
Kontoyiannis, Dimitrios P., Chamilos, Georgios, Lewis, Russell E., Giralt, Sergio, Cortes, Jorge, Raad, Issam I., Manning, John T., and Xin Han
- Subjects
LEUKEMIA ,BONE marrow ,GRAFT versus host disease ,HEMATOPOIETIC stem cells ,ASPERGILLOSIS ,STEM cell transplantation - Abstract
This article discusses findings of a study, which evaluated the bone marrow iron stores in patients with leukemia as well as recipients of allogeneic hematopoietic stem cell transplantation with invasive aspergillosis (IA) and those without fungal infections. IA is considered a risk among patients with leukemia and those who have undergone hematopoietic stem cell transplantation.
- Published
- 2007
- Full Text
- View/download PDF
9. Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of High-Risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome Using Reduced-Intensity Conditioning with Fludarabine and Melphalan
- Author
-
Oran, Betul, Giralt, Sergio, Saliba, Rima, Hosing, Chitra, Popat, Uday, Khouri, Issa, Couriel, Daniel, Qazilbash, Muzaffar, Anderlini, Paolo, Kebriaei, Partow, Ghosh, Shubhra, Carrasco-Yalan, Antonio, de Meis, Ernesto, Anagnostopoulos, Athanasios, Donato, Michele, Champlin, Richard E., and de Lima, Marcos
- Subjects
- *
ACUTE myeloid leukemia , *MYELODYSPLASTIC syndromes , *HEMATOPOIETIC stem cell transplantation , *GRAFT versus host disease - Abstract
Abstract: Reduced-intensity conditioning has extended the use of allogeneic hematopoietic stem cell transplantation (HSCT) to patients otherwise not eligible for this treatment due to older age or frailty. One hundred twelve acute myelogenous leukemia/myelodysplastic syndromes patients received fludarabine and melphalan (FM) conditioning with allogeneic HSCT. Most patients (73%) were not in remission. Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus and mini-methotrexate. Median age was 55 years (range, 22-74). Donors were related (53%) and unrelated (47%). Median follow-up of surviving patients (n = 43) was 29.4 months (range, 13.1-87.7). The complete remission (CR) rate was 82%. Estimates of 2-year survival were 66%, 40%, and 23% for patients in CR, with active disease without and with circulating blasts at HSCT, respectively. In multivariate analysis, survival was negatively influenced by active disease at HSCT and development of grade II-IV acute GVHD. Presence of circulating blasts at HSCT negatively influenced freedom from disease progression. Incidence of nonrelapse mortality (NRM) was significantly higher for patients with active disease, but was not influenced by patient age. Patients in CR had a day-100 and 2-year NRM of 0% and 20%, respectively. Use of unrelated donors increased the risk of NRM only among patients with active disease. FM and HSCT elicited long-term disease control in a significant fraction of this high-risk cohort. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
10. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy.
- Author
-
Champlin, Richard, Khouri, Issa, Shimoni, Avichai, Gajewski, James, Kornblau, Steven, Molldrem, Jeffrey, Ueno, Naoto, Giralt, Sergio, and Anderlini, Paolo
- Subjects
GRAFT versus host disease ,BONE marrow transplant complications - Abstract
Examines the association of the therapeutic benefit of allogeneic bone marrow transplantation with immune-mediated graft-versus-malignancy effect. Information on graft-versus-malignancy; Susceptibility of the disease to graft-versus-malignancy; Separation of graft-versus-malignancy from graft-versus-host diseases.
- Published
- 2000
- Full Text
- View/download PDF
11. Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC.
- Author
-
Malard, Florent, Labopin, Myriam, Cho, Christina, Blaise, Didier, Papadopoulos, Esperanza B., Passweg, Jakob, O'Reilly, Richard, Forcade, Edouard, Maloy, Molly, Volin, Liisa, Castro-Malaspina, Hugo, Hicheri, Yosr, Jakubowski, Ann A., Orvain, Corentin, Giralt, Sergio, Mohty, Mohamad, Nagler, Arnon, and Perales, Miguel-Angel
- Subjects
GRAFT versus host disease ,CELL transplantation ,DISEASE relapse ,MYELOID leukemia ,BONE marrow ,CYTOGENETICS - Abstract
Background: Graft-versus-host disease (GVHD) is one of the leading causes of non-relapse mortality and morbidity after allogeneic hematopoietic stem cell transplantation (allo-HCT). Methods: We evaluated the outcomes of two well-established strategies used for GVHD prevention: in vivo T cell depletion using antithymocyte globulin (ATG) and ex vivo T cell depletion using a CD34-selected (CD34+) graft. A total of 525 adult patients (363 ATG, 162 CD34+) with intermediate or high-risk cytogenetics acute myeloid leukemia (AML) in first complete remission (CR1) were included. Patients underwent myeloablative allo-HCT using matched related or unrelated donors. Results: Two-year overall survival estimate was 69.9% (95% CI, 58.5–69.4) in the ATG group and 67.6% (95% CI, 60.3–74.9) in the CD34+ group (p = 0.31). The cumulative incidence of grade II–IV acute GVHD and chronic GVHD was higher in the ATG cohort [HR 2.0 (95% CI 1.1–3.7), p = 0.02; HR 15.1 (95% CI 5.3–42.2), p < 0.0001]. Parameters associated with a lower GVHD-free relapse-free survival (GRFS) were ATG [HR 1.6 (95% CI 1.1–2.2), p = 0.006], adverse cytogenetic [HR 1.7 (95% CI 1.3–2.2), p = 0.0004], and the use of an unrelated donor [HR 1.4 (95% CI 1.0–1.9), p = 0.02]. There were no statistical differences between ATG and CD34+ in terms of relapse [HR 1.52 (95% CI 0.96–2.42), p = 0.07], non-relapse mortality [HR 0.96 (95% CI 0.54–1.74), p = 0.90], overall survival [HR 1.43 (95% CI 0.97–2.11), p = 0.07], and leukemia-free survival [HR 1.25 (95% CI 0.88–1.78), p = 0.21]. Significantly, more deaths related to infection occurred in the CD34+ group (16/52 vs. 19/112, p = 0.04). Conclusions: These data suggest that both ex vivo CD34-selected and in vivo ATG T cell depletion are associated with a rather high OS and should be compared in a prospective randomized trial. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
12. Presalvage International Staging System Stage and Other Important Outcome Associations in CD34+-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma.
- Author
-
Bryant, Adam R., Hilden, Patrick, Giralt, Sergio, Chung, David J., Maloy, Molly, Landau, Heather, Landgren, Ola, Scordo, Michael, Shah, Gunjan, Smith, Eric L., O'Reilly, Richard J., Perales, Miguel-Angel, and Koehne, Guenther
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *ALEMTUZUMAB , *MULTIPLE myeloma , *DRUG resistance in cancer cells , *CELL transplantation , *GRAFT versus host disease - Abstract
Despite ongoing therapeutic advances, multiple myeloma (MM) remains largely incurable, and outcomes in patients who develop resistance to immunomodulatory drugs or proteasome inhibitors remain grim. Allogeneic hematopoietic cell transplantation (alloHCT) is an alternative option that may offer potential for cure. Although rates of transplantation-related morbidity and mortality have decreased in recent years, weighing this approach's potential benefits against nontransplantation therapies demands a thoroughly informed pre-alloHCT assessment. Here we assess the impact of pre-alloHCT variables on important clinical outcomes in a large cohort of relapsed refractory MM (RRMM) CD34+-selected alloHCT recipients. We included all patients with MM who underwent CD34+-selected alloHCT at our center between June 2010 and December 2015. Patients were conditioned with busulfan (0.8 mg/kg × 10), melphalan (70 mg/m2 × 2), and fludarabine (25 mg/m2 × 5), followed by infusion of a CD34+-selected peripheral blood stem cell graft, without post-alloHCT graft-versus-host disease (GVHD) prophylaxis. The 73-patient cohort had a median age of 55 years (range, 37 to 66 years). Overall survival (OS) and progression-free survival (PFS) rates were 70% and 53%, respectively, at 1 year (95% confidence interval [CI], 58% to 79% and 41% to 64%) and 50% and 30%, respectively, at 3 years (95% CI, 38% to 62% and 19% to 41%). The cumulative incidence of relapse was 25% at 1 year (95% CI, 15% to 35%) and 47% at 3 years (95% CI, 35% to 58%). Nonrelapse mortality at 1 year was 22% (95% CI, 13% to 32%). The cumulative incidence of grade II-IV acute GVHD (aGVHD) was 7% at 100 days (95% CI, 3% to 14%), and that of any chronic GVHD (cGVHD) was 8% at 1 year (95% CI, 3% to 16%). International Staging System (ISS) stage II-III assessed before salvage therapy was associated with poorer 3-year OS (30% versus 54%; P =.037) and 3-year PFS (9% versus 33%; P =.013), and increased 3-year relapse incidence (72% versus 39%; P =.004). Older age and GVHD before 6 months (aGVHD grade II-IV or cGVHD of any grade) were also associated with poorer OS, and a greater number of pre-alloHCT lines of therapy was also associated with increased relapse incidence. Our findings reinforce that CD34+-selected alloHCT can achieve prolonged disease control and long-term survival in high- risk, heavily treated refractory MM populations. We also identified numerous pre-alloHCT variables associated with OS, PFS, and relapse. Amongst these, presalvage ISS stage II-III was consistently associated with poorer survival and relapse outcomes. Given the lack of established alternate therapies for patients with RRMM, we advocate the identification of adverse pre-alloHCT variables to inform alloHCT decision making rather than to exclude patient cohorts from this potentially curative treatment option. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. ATG and RIC: not such a good match?
- Author
-
Giralt, Sergio
- Subjects
- *
GRAFT versus host disease , *IMMUNOTHERAPY , *TRANSPLANTATION immunology , *BONE marrow transplantation , *GLOBULINS , *THERAPEUTICS - Abstract
In this article, the author discusses the topic on the use of nonspecific immunotherapy for the medication of secondary disease after allogeneic transplantation. It mentions the application of antithymocyte globulin (ATG) as prophylaxis of acute graft versus host disease (GVHD). The result of reduced intensity conditioning (RIC) is also examined.
- Published
- 2011
- Full Text
- View/download PDF
14. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation
- Author
-
Couriel, Daniel R., Saliba, Rima M., Giralt, Sergio, Khouri, Issa, Andersson, Borje, de Lima, Marcos, Hosing, Chitra, Anderlini, Paolo, Donato, Michelle, Cleary, Karen, Gajewski, James, Neumann, Joyce, Ippoliti, Cindy, Rondon, Gabriela, Cohen, Agueda, and Champlin, Richard
- Subjects
- *
HEMATOPOIETIC stem cells , *GRAFT versus host disease , *MORTALITY , *PATIENTS - Abstract
In this study, we evaluated the influence of nonmyeloablative and ablative conditioning regimens on the occurrence of acute and chronic graft-versus-host disease (GVHD). One hundred thirty-seven patients undergoing matched-related sibling transplantations received the same GVHD prophylaxis. Myeloablative regimens included intravenous busulfan/cyclophosphamide (n = 45) and fludarabine/melphalan (n = 29). Patients in the nonmyeloablative group (n = 63) received fludarabine/idarubicin/cytarabine, cisplatin/fludarabine/idarubicin, and fludarabine/cyclophosphamide. The actuarial rate of grade II to IV acute GVHD was significantly higher (hazard ratio, 3.6; 95% confidence interval, 1.5–8.8) in patients receiving ablative regimens (36%) compared with the nonmyeloablative group (12%). The cumulative incidence of chronic GVHD was higher in the ablative group (40%) compared with the nonmyeloablative group (14%). The rates were comparable within the first 200 days and were significantly higher in the ablative group beyond day 200 (hazard ratio, 5.2; 95% confidence interval, 1.2–23.2). Nonrelapse and GVHD-related mortality were relatively low in both groups. The use of the described nonmyeloablative preparative regimens was associated with a reduced incidence of grade II to IV acute GVHD and chronic GVHD compared with the busulfan/cyclophosphamide and fludarabine/melphalan transplant regimens. It is interesting to note that nonrelapse mortality with nonmyeloablative regimens in older and more debilitated patients was low (14%) and comparable to that achieved with standard high-dose regimens in younger patients [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
15. Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation.
- Author
-
Prockop, Susan, Doubrovina, Ekaterina, Suser, Stephanie, Heller, Glenn, Barker, Juliet, Dahi, Parastoo, Perales, Miguel A., Papadopoulos, Esperanza, Sauter, Craig, Castro-Malaspina, Hugo, Boulad, Farid, Curran, Kevin J., Giralt, Sergio, Gyurkocza, Boglarka, Hsu, Katharine C., Jakubowski, Ann, Hanash, Alan M., Kernan, Nancy A., Kobos, Rachel, and Koehne, Guenther
- Subjects
- *
T cells , *INSTITUTIONAL review boards , *SKIN diseases , *TRANSPLANTATION of organs, tissues, etc. , *GRAFT versus host disease , *LYMPHOMA treatment , *TREATMENT of Epstein-Barr virus diseases , *RESEARCH , *IMMUNIZATION , *HOMOGRAFTS , *CLINICAL trials , *RESEARCH methodology , *PROGNOSIS , *EVALUATION research , *MEDICAL cooperation , *COMPARATIVE studies , *EPSTEIN-Barr virus , *HEMATOPOIETIC stem cell transplantation , *LYMPHOMAS , *EPSTEIN-Barr virus diseases - Abstract
BACKGROUNDAdoptive transfer of donor-derived EBV-specific cytotoxic T-lymphocytes (EBV-CTLs) can eradicate EBV-associated lymphomas (EBV-PTLD) after transplantation of hematopoietic cell (HCT) or solid organ (SOT) but is unavailable for most patients.METHODSWe developed a third-party, allogeneic, off-the-shelf bank of 330 GMP-grade EBV-CTL lines from specifically consented healthy HCT donors. We treated 46 recipients of HCT (n = 33) or SOT (n = 13) with established EBV-PTLD, who had failed rituximab therapy, with third-party EBV-CTLs. Treatment cycles consisted of 3 weekly infusions of EBV-CTLs and 3 weeks of observation.RESULTSEBV-CTLs did not induce significant toxicities. One patient developed grade I skin graft-versus-host disease. Complete remission (CR) or sustained partial remission (PR) was achieved in 68% of HCT recipients and 54% of SOT recipients. For patients who achieved CR/PR or stable disease after cycle 1, one year overall survival was 88.9% and 81.8%, respectively. In addition, 3 of 5 recipients with POD after a first cycle who received EBV-CTLs from a different donor achieved CR or durable PR (60%) and survived longer than 1 year. Maximal responses were achieved after a median of 2 cycles.CONCLUSIONThird-party EBV-CTLs of defined HLA restriction provide safe, immediately accessible treatment for EBV-PTLD. Secondary treatment with EBV-CTLs restricted by a different HLA allele (switch therapy) can also induce remissions if initial EBV-CTLs are ineffective. These results suggest a promising potential therapy for patients with rituximab-refractory EBV-associated lymphoma after transplantation.TRIAL REGISTRATIONPhase II protocols (NCT01498484 and NCT00002663) were approved by the Institutional Review Board at Memorial Sloan Kettering Cancer Center, the FDA, and the National Marrow Donor Program.FUNDINGThis work was supported by NIH grants CA23766 and R21CA162002, the Aubrey Fund, the Claire Tow Foundation, the Major Family Foundation, the Max Cure Foundation, the Richard "Rick" J. Eisemann Pediatric Research Fund, the Banbury Foundation, the Edith Robertson Foundation, and the Larry Smead Foundation. Atara Biotherapeutics licensed the bank of third-party EBV-CTLs from Memorial Sloan Kettering Cancer Center in June 2015. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
16. Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease.
- Author
-
Montoro, Juan, Ceberio, Izaskun, Hilden, Patrick, Maloy, Molly A., Barker, Juliet, Castro-Malaspina, Hugo, Dahi, Parastoo, Koehne, Guenther, Perales, Miguel-Angel, Ponce, Doris, Sauter, Craig, Shaffer, Brian, Tamari, Roni, Young, James W., Giralt, Sergio A., O'Reilly, Richard J., Jakubowski, Ann A., and Papadopoulos, Esperanza B.
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *ACUTE myeloid leukemia , *GRAFT versus host disease , *ALEMTUZUMAB , *PROGRESSION-free survival , *HEMATOPOIETIC stem cells , *STEM cell transplantation - Abstract
• Ex vivo T cell-depleted (TCD) hematopoietic stem cell transplantation (HSCT) in patients with acute myelogenous leukemia (AML) in first or second complete remission (CR1/CR2) is associated with comparable overall survival and disease-free survival to unmodified HSCT. • Transplantation outcomes are similar in patients with AML CR1/CR2 following TCD HSCT. • The risk of relapse after ex vivo TCD HSCT is no higher than after unmodified HSCT. • Ex vivo TCD HSCT is associated with a significantly lower rate of graft-versus-host disease compared with unmodified HSCT. Large series of patients with acute myelogenous leukemia (AML) after ex vivo T cell-depleted (TCD) allogeneic hematopoietic stem cell transplantation (allo-HSCT) have not been reported previously. We retrospectively analyzed the outcomes of 266 patients (median age, 54 years) with AML who received CD34-selected TCD allo-HSCTs while in first (75%) or second (25%) complete remission (CR1/CR2) at a single institution. The conditioning regimens were all myeloablative, and no additional graft-versus-host disease (GVHD) prophylaxis was given. The cumulative incidences of grade II-IV and grade III-IV acute GVHD at 180 days were 14% (95% confidence interval [CI], 10% to 18%) and 3% (95% CI, 1% to 5%), respectively. The cumulative incidence of chronic GVHD at 3 years was 3% (95% CI, 1% to 6%). The 3-year cumulative incidence of nonrelapse mortality was 21% (95% CI, 16% to 26%) and that of relapse was 21% (95% CI, 17% to 27%). Overall survival (OS) and disease-free survival (DFS) at 1, 3, and 5 years were 75%, 61%, and 56% and 68%, 57%, and 53%, respectively. There were no significant differences in OS, DFS, and relapse rates for patients who underwent transplantation in CR1 and those who did so in CR2. However, patients with high-risk cytogenetics at diagnosis had significantly poorer outcomes. The OS and DFS rates compare favorably with those for unmodified allo-HSCT, but with considerably lower rates of GVHD. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation.
- Author
-
Scordo, Michael, Bhatt, Valkal, Hilden, Patrick, Smith, Melody, Thoren, Katie, Cho, Christina, Shah, Gunjan L., Maloy, Molly A., Papadopoulos, Esperanza B., Jakubowski, Ann A., Avecilla, Scott T., O'Reilly, Richard J., Castro-Malaspina, Hugo, Tamari, Roni, Shaffer, Brian C., Boelens, Jaap J., Perales, Miguel-Angel, and Giralt, Sergio A.
- Subjects
- *
LYMPHOCYTE count , *CELL transplantation , *GLOBULINS , *GRAFT rejection , *GRAFT versus host disease , *HEMATOLOGIC malignancies - Abstract
• Antithymocyte globulin (ATG) is given with the patient in a lymphodepleted state before ex vivo CD34+ selected allogeneic hematopoietic cell transplantation. • Standard weight-based ATG dosing results in heavier patients receiving high total ATG doses. • High total ATG doses results in higher nonrelapse mortality and inferior disease-free survival and overall survival. Antithymocyte globulin (ATG) use mitigates the risk of graft rejection and graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (allo-HCT), but ATG overexposure in the setting of lymphopenia negatively affects immune recovery. We hypothesized that standard empiric weight-based dosing of ATG, used to prevent graft rejection in ex vivo CD34-selected allo-HCT, may lead to serious adverse consequences on outcomes in certain patients. We evaluated 304 patients undergoing myeloablative-conditioned ex vivo CD34-selected allo-HCT with HLA-matched donors for the treatment of hematologic malignancies. Patients received rabbit ATG at a dose of 2.5 mg/kg/day i.v. on days -3 and/or -2. An ATG dosing cutoff of 450 mg was used for statistical analyses to assess the relationship between ATG and overall survival (OS). Among all patients, median total ATG dose was 360 mg (range, 130 to 510 mg); 279 (92%) received a total dose of ATG ≤450 mg, and 25 (8%) received a total dose >450 mg. On the first day of ATG administration (day -3), the median absolute lymphocyte count was.0 K/µL. For patients who received a total dose of ATG >450 mg or ≤450 mg, the incidences of acute and late-acute GVHD grade II-IV were statistically similar. At 3 years post-HCT, for patients who received a total dose of ATG >450 mg or ≤450 mg, nonrelapse mortality (NRM) rates were 35% and 18%, respectively (P =.029), disease-free survival (DFS) rates were 37% and 61%, respectively (P =.003), and OS rates were 40% and 67%, respectively (P =.001). Among all patient and HCT characteristics in multivariable analyses, receipt of a total dose of ATG >450 mg was associated with an increased risk of NRM (hazard ratio [HR], 2.9; P =.01), shorter DFS (HR, 2.0; P =.03), and inferior OS (HR, 2.1; P =.01). In summary, the use of weight-based ATG at a time of relative lymphopenia before ex vivo CD34-selected allo-HCT results in overdosing in heavier patients, leading to higher NRM and lower DFS and OS. Further pharmacokinetic investigation in this setting is critical to determining the optimal dosing strategy for ATG. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
18. Early Fluid Overload Is Associated with an Increased Risk of Nonrelapse Mortality after Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation.
- Author
-
Rondon-Clavo, Carlos, Scordo, Michael, Hilden, Patrick, Shah, Gunjan L., Cho, Christina, Maloy, Molly A., Papadopoulos, Esperanza B., Jakubowski, Ann A., O'Reilly, Richard J., Gyurkocza, Boglarka, Castro-Malaspina, Hugo, Tamari, Roni, Shaffer, Brian C., Perales, Miguel-Angel, Jaimes, Edgar A., and Giralt, Sergio A.
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *GRAFT versus host disease , *PREVENTIVE medicine , *CALCINEURIN , *CANCER chemotherapy - Abstract
Highlights • We applied a novel grading system to assess the effects of early fluid overload (FO) on outcomes in patients after ex vivo CD34+ selected allo-HCT. • Patients with grade ≥ 2 FO had significantly higher NRM than those with grade < 2 FO. • Even in the absence of CNI-based GVHD prophylaxis, FO remains a highly relevant early transplant toxicity that should be routinely assessed. Abstract In a recently published and validated definition of fluid overload (FO), grade ≥ 2 FO was significantly associated with an increased risk of nonrelapse mortality (NRM) after unmodified and haploidentical allogeneic hematopoietic cell transplantation (allo-HCT) using calcineurin inhibitor (CNI)-based graft-versus-host disease (GVHD) prophylaxis. We evaluated the effect of FO on outcomes in 169 patients undergoing myeloablative-conditioned ex vivo CD34+ selected allo-HCT using the same grading scale. Thirty patients (17.8%) had grade ≥ 2 FO within the 30 days after ex vivo CD34+ selected allo-HCT with a median onset at day 11 (range, -8 to 28). Age ≥ 55 years (odds ratio, 3.43; P =.005) and chemotherapy-based conditioning (odds ratio, 3.89; P =.007) were associated with an increased risk of grade ≥ 2 FO. Patients with early grade ≥ 2 FO had a significantly higher NRM when compared with patients with grade < 2 FO (24.1% versus 3.6% at day 100, P =.01). The HCT-specific comorbidity index (HCT-CI) ≥ 3, FEV 1 < 80, adjusted DL co < 80, and HLA mismatch were associated with an increased risk of NRM, whereas total body irradiation–based conditioning was associated with a reduced risk of NRM. In a multivariate analysis grade ≥ 2 FO was associated with increased NRM after adjusting for HCT-CI and HLA match (hazard ratio, 2.3; P =.014). There was a trend toward inferior relapse-free survival in patients with grade ≥ 2 FO compared with patients with grade < 2 FO, 62% versus 72% at 1 year (P =.07), and a trend toward inferior overall survival, 69% versus 79% at 1 year (P = 0.06), respectively. Our findings show that FO should be routinely assessed to identify patients at risk for NRM. Despite a CNI-free allo-HCT platform, regimen-related tissue and endothelial injury leads to FO in susceptible patients. FO is a highly relevant post-HCT toxicity that requires further inquiry. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
19. CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes.
- Author
-
de Lima, Marcos, Oran, Betul, Champlin, Richard E., Papadopoulos, Esperanza B., Giralt, Sergio A., Scott, Bart L., William, Basem M., Hetzer, Joel, Laille, Eric, Hubbell, Becky, Skikne, Barry S., and Craddock, Charles
- Subjects
- *
STEM cell transplantation , *ACUTE myeloid leukemia , *MYELODYSPLASTIC syndromes , *AZACITIDINE , *GRAFT versus host disease , *PHARMACOKINETICS - Abstract
Highlights • Azacitidine post-transplant maintenance may promote a graft-versus-leukemia effect and reduce GVHD. • Extended oral CC-486 dosing may prolong epigenetic regulation post-allograft. • CC-486 post-transplant maintenance was associated with low rates of relapse and GVHD. • One-year relapse- and progression-free survival rate was 72% with 14-day CC-486 dosing. • Recommended dose is 200 mg daily for 14 days per 28-day cycle. Abstract Relapse is the main cause of treatment failure after allogeneic stem cell transplant (alloSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Injectable azacitidine can improve post-transplant outcomes but presents challenges with exposure and compliance. Oral CC-486 allows extended dosing to prolong azacitidine activity. We investigated use of CC-486 maintenance therapy after alloSCT. Adults with MDS or AML in morphologic complete remission at CC-486 initiation (42 to 84 days after alloSCT) were included. Patients received 1 of 4 CC-486 dosing schedules per 28-day cycle for up to 12 cycles. Endpoints included safety, pharmacokinetics, graft-versus-host disease (GVHD) incidence, relapse/progression rate, and survival. Of 30 patients, 7 received CC-486 once daily for 7 days per cycle (200 mg, n = 3; 300 mg, n = 4) and 23 for 14 days per cycle (150 mg, n = 4; 200 mg, n = 19 [expansion cohort]). Grades 3 to 4 adverse events were infrequent and occurred with similar frequency across regimens. Standard concomitant medications did not alter CC-486 pharmacokinetic parameters. Three patients (10%) experienced grade III acute GVHD and 9 experienced chronic GVHD. Of 28 evaluable patients, 6 (21%) relapsed or had progressive disease: 3 of 7 patients (43%) who had received 7-day dosing and 3 of 23 (13%) who had received 14-day dosing. Transplant-related mortality was 3%. At 19 months of follow-up, median overall survival was not reached. Estimated 1-year survival rates were 86% and 81% in the 7-day and 14-day dosing cohorts, respectively. CC-486 maintenance was generally well tolerated, with low rates of relapse, disease progression, and GVHD. CC-486 maintenance may permit epigenetic manipulation of the alloreactive response postallograft. Findings require confirmation in randomized trials. (ClinicalTrials.gov NCT01835587.) [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
20. T Cell Depletion as an Alternative Approach for Patients 55 Years or Older Undergoing Allogeneic Stem Cell Transplantation as Curative Therapy for Hematologic Malignancies.
- Author
-
Jakubowski, Ann A., Petrlik, Erica, Maloy, Molly, Hilden, Patrick, Papadopoulos, Esperanza, Young, James W., Boulad, Farid, Castro-Malaspina, Hugo, Tamari, Roni, Dahi, Parastoo B., Goldberg, Jenna, Koehne, Guenther, Perales, Miguel-Angel, Sauter, Craig S., O'Reilly, Richard J., and Giralt, Sergio
- Subjects
- *
STEM cell transplantation , *T cells , *GRAFT versus host disease , *HEMATOPOIETIC stem cell transplantation , *HEALTH of older people - Abstract
T cell–depleted (TCD) allogeneic hematopoietic stem cell transplantation (HSCT) is curative treatment for hematologic malignancies in adults, shown to reduce graft-versus-host disease (GVHD) without increased relapse. We retrospectively reviewed a single-center, 11-year experience of 214 patients aged ≥ 55 years to determine tolerability and efficacy in the older adult. Most patients (70%) had myeloid diseases, and most acute leukemias were in remission. Median age was 61 years, with related and unrelated donors ≥8/10 HLA matched. Hematopoietic cell transplantation–specific comorbidity index scores were intermediate and high for 84%. Conditioning regimens were all myeloablative. Grafts were peripheral blood stem cells (97%) containing CD3 dose ≤10 3-4 /kg body weight, without pharmacologic GVHD prophylaxis. With median follow-up of 70 months among survivors, Kaplan-Meier estimates of overall and relapse-free survival were 44% and 41%, respectively (4 years). Cumulative incidence of nonrelapse mortality at day +100 was only 10%. Incidence of GVHD for acute (grades II to IV) was 9% at day +100 and for chronic was 7% at 2 and 4 years (8 extensive, 1 overlap). Median Karnofsky performance status for patients > 2 years post-transplant was 90%. As 1 of the largest reports for patients ≥2 aged ≥55 years receiving TCD HSCTs, it demonstrates curative therapy with minimal GVHD, similar to that observed in a younger population. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
21. Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34+ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation.
- Author
-
Barba, Pere, Ratan, Ravin, Cho, Christina, Ceberio, Izaskun, Hilden, Patrick, Devlin, Sean M., Maloy, Molly A., Barker, Juliet N., Castro-Malaspina, Hugo, Jakubowski, Ann A., Koehne, Guenther, Papadopoulos, Esperanza B., Ponce, Doris M., Sauter, Craig, Tamari, Roni, van den Brink, Marcel R.M., Young, James W., O'Reilly, Richard J., Giralt, Sergio A., and Perales, Miguel-Angel
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *GRAFT versus host disease , *COMORBIDITY , *ACUTE myeloid leukemia , *MYELODYSPLASTIC syndromes - Abstract
To evaluate the association between the hematopoietic cell transplantation-comorbidity index (HCT-CI) and the recently developed age-adjusted HCT-CI (HCT-CI/age) and transplant outcomes in the setting of CD34-selected allogeneic HCT, we analyzed a homogeneous population of patients undergoing allogeneic HCT with CD34-selected grafts for acute myeloid leukemia and myelodysplastic syndrome (n = 346). Median HCT-CI and HCT-CI/age scores were 2 (percentile 25 to 75, 1 to 4) and 3 (percentile 25 to 75, 1 to 5), respectively. Higher HCT-CI and HCT-CI/age scores were associated with higher nonrelapse mortality (NRM) and lower overall survival (OS). The HCT-CI distinguished 2 risk groups (0 to 2 versus ≥3), whereas, with the HCT-CI/age, there was a progressive increase in NRM and decrease in OS with increasing scores in all 4 groups (0 versus 1 to 2 versus 3 to 4 versus ≥5). Higher scores in both models were associated with lower chronic graft-versus-host disease relapse-free survival but not with higher relapse. Both models showed a promising predictive accuracy for NRM (c− = .616 for HCT-CI and c− = .647 for HCT-CI/age). In conclusion, the HCT-CI and HCT-CI/age predict transplant outcomes in CD34-selected allo-HCT, including NRM, OS, and chronic graft-versus-host disease relapse-free survival and may be used to select appropriate patients for this approach. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
22. CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse.
- Author
-
Tamari, Roni, Chung, Stephen S., Papadopoulos, Esperanza B., Jakubowski, Ann A., Hilden, Patrick, Devlin, Sean M., Goldberg, Jenna D., Perales, Miguel-Angel, Ponce, Doris M., Sauter, Craig S., Maloy, Molly A., Herman, Dara Y., Klimek, Virginia, Young, James W., O'Reilly, Richard J., Giralt, Sergio A., and Castro-Malaspina, Hugo
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *CD34 antigen , *MYELOSUPPRESSION , *GLOBULINS , *MYELODYSPLASTIC syndromes , *GRAFT versus host disease - Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative therapy for patients with myelodysplastic syndrome (MDS). Donor T cells are critical for the graft-versus-tumor effect but carry the risk of graft-versus-host disease (GVHD). CD34 selection with immunomagnetic beads has been an effective method of depleting alloreactive donor T cells from the peripheral blood graft and has been shown to result in significant reduction in acute and chronic GVHD. We analyzed the outcomes of 102 adults (median age, 57.6 years) with advanced MDS who received a CD34-selected allo-HSCT between January 1997 and April 2012 at Memorial Sloan Kettering Cancer Center. The cumulative incidences of grades II to IV acute GVHD were 9.8% at day 100 (95% confidence interval [CI], 5.0% to 16.5%) and 15.7% at day 180 (95% CI, 9.4% to 23.4%). The cumulative incidence of chronic GVHD at 1 year was 3.9% (95% CI, 1.3% to 9.0%). The cumulative incidences of relapse were 11.8% at 1 year (95% CI, 6.4% to 18.9%) and 15.7% at 2 years (95% CI, 9.4% to 23.4%). Forty-eight patients were alive with a median follow-up of 71.7 months. Rates of overall survival (OS) were 56.9% at 2 years (95% CI, 48% to 67.3%) and 49.3% at 5 years (95% CI, 40.4% to 60.2%). Rates of relapse-free survival (RFS) were 52.0% at 2 years (95% CI, 41.9% to 61.1%) and 47.6% at 5 years (95% CI, 37.5% to 56.9%). The cumulative incidences of nonrelapse mortality were 7.8% at day 100 (95% CI, 3.7% to 14.1%), 22.5% at 1 year (95% CI, 15.0% to 31.1%), and 33.4% at 5 years (95% CI, 24.2% to 42.6%) post-transplant. The incidence of chronic GVHD/RFS overlapped with RFS. These findings demonstrate that ex vivo T cell–depleted allo-HSCT by CD34 selection offers long-term OS and RFS with low incidences of acute and chronic GVHD and without an increased risk of relapse. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
23. Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation.
- Author
-
Majhail, Navneet S., Farnia, Stephanie H., Carpenter, Paul A., Champlin, Richard E., Crawford, Stephen, Marks, David I., Omel, James L., Orchard, Paul J., Palmer, Jeanne, Saber, Wael, Savani, Bipin N., Veys, Paul A., Bredeson, Christopher N., Giralt, Sergio A., and LeMaistre, Charles F.
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *GRAFT versus host disease , *BONE marrow transplantation , *MEDICAL care , *CLINICAL trials - Abstract
Approximately 20,000 hematopoietic cell transplantation (HCT) procedures are performed in the United States annually. With advances in transplantation technology and supportive care practices, HCT has become safer, and patient survival continues to improve over time. Indications for HCT continue to evolve as research refines the role for HCT in established indications and identifies emerging indications where HCT may be beneficial. The American Society for Blood and Marrow Transplantation (ASBMT) established a multiple-stakeholder task force consisting of transplant experts, payer representatives, and a patient advocate to provide guidance on “routine” indications for HCT. This white paper presents the recommendations from the task force. Indications for HCT were categorized as follows: (1) Standard of care, where indication for HCT is well defined and supported by evidence; (2) Standard of care, clinical evidence available, where large clinical trials and observational studies are not available but HCT has been shown to be effective therapy; (3) Standard of care, rare indication, for rare diseases where HCT has demonstrated effectiveness but large clinical trials and observational studies are not feasible; (4) Developmental, for diseases where preclinical and/or early phase clinical studies show HCT to be a promising treatment option; and (5) Not generally recommended, where available evidence does not support the routine use of HCT. The ASBMT will periodically review these guidelines and will update them as new evidence becomes available. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
24. Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation.
- Author
-
Harnicar, Stephen, Ponce, Doris M., Hilden, Patrick, Zheng, Junting, Devlin, Sean M., Lubin, Marissa, Pozotrigo, Melissa, Mathew, Sherry, Adel, Nelly, Kernan, Nancy A., O'Reilly, Richard, Prockop, Susan, Scaradavou, Andromachi, Hanash, Alan, Jenq, Robert, van den Brink, Marcel, Giralt, Sergio, Perales, Miguel A., Young, James W., and Barker, Juliet N.
- Subjects
- *
MYCOPHENOLIC acid , *GRAFT versus host disease , *ADRENOCORTICAL hormones , *DRUG dosage , *IMMUNOSUPPRESSION , *CORD blood transplantation , *THERAPEUTICS - Abstract
Although mycophenolate mofetil (MMF) has replaced corticosteroids as immunosuppression in cord blood transplantation (CBT), optimal MMF dosing has yet to be established. We intensified MMF dosing from every 12 to every 8 hours to augment graft-versus-host disease (GVHD) prophylaxis in double-unit cord blood transplantation (dCBT) and evaluated outcomes according to the total daily MMF dose/kg in 174 dCBT recipients (median age, 39 years; range, 1 to 71) who underwent transplantation for hematologic malignancies. Recipients of an MMF dose ≤ the median (36 mg/kg/day) had an increased day 100 grade III and IV acute GVHD (aGVHD) incidence compared with patients who received >36 mg/kg/day (24% versus 8%, P = .008). Recipients of ≤ the median dose who had highly HLA allele (1 to 3 of 6) mismatched dominant units had the highest day 100 grade III and IV aGVHD incidence of 37% ( P = .009). This finding was confirmed in multivariate analysis ( P = .053). In 83 patients evaluated for mycophenolic acid (MPA) troughs, those with a mean week 1 and 2 trough < .5 μg/mL had an increased day 100 grade III and IV aGVHD of 26% versus 9% ( P = .063), and those who received a low total daily MMF dose and had a low mean week 1 and 2 MPA trough had a 40% incidence ( P = .008). Higher MMF dosing or MPA troughs had no impact on engraftment after myeloablation. This analysis supports intensified MMF dosing in milligram per kilogram per day and MPA trough level monitoring early after transplantation in dCBT recipients. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
25. High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation.
- Author
-
Ponce, Doris M., Hilden, Patrick, Mumaw, Christen, Devlin, Sean M., Lubin, Marissa, Giralt, Sergio, Goldberg, Jenna D., Hanash, Alan, Hsu, Katharine, Jenq, Robert, Perales, Miguel-Angel, Sauter, Craig, van den Brink, Marcel R. M., Young, James W., Brentjens, Renier, Kernan, Nancy A., Prockop, Susan E., O'Reilly, Richard J., Scaradavou, Andromachi, and Paczesny, Sophie
- Subjects
- *
CORD blood transplantation , *GRAFT versus host disease , *MORTALITY , *SURGICAL complications , *BIOMARKERS , *TUMOR necrosis factors , *INTERLEUKIN-8 , *ISLANDS of Langerhans - Abstract
While cord blood transplantation (CBT) is an effective therapy for hematologic malignancies, acute graft-versus-host disease (aGVHD) is a leading cause of transplant-related mortality (TRM). We investigated if biomarkers could predict aGVHD and TRM after day 28 in CBT recipients. Day 28 samples from 113 CBT patients were analyzed. Suppressor of tumorigenicity 2 (ST2) was the only biomarker associated with grades ll-IV and lll-IV aGVHD and TRM. Day 180 grade lll-IV aGVHD in patients with high ST2 levels was 30% (95% confidence interval [Cl], 18-43) vs 13% (95% Cl, 5-23) in patients with low levels (P = .024). The adverse effect of elevated ST2 was independent of HLA match. Moreover, high day 28 ST2 levels were associated with increased TRM with day 180 estimates of 23% (95% Cl, 13-35) vs 5% (95% Cl, 1-13) if levels were low (P = .001). GVHD was the most common cause of death in high ST2 patients. High concentrations of tumor necrosis factor receptor-1, interleukin-8, and regenerating islet-derived protein 3-a were also associated with TRM. Our results are consistent with those of adult donor allografts and warrant further prospective evaluation to facilitate future therapeutic intervention to ameliorate severe aGVHD and further improve survival after CBT. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
26. Lenalidomide Maintenance for High-Risk Multiple Myeloma after Allogeneic Hematopoietic Cell Transplantation.
- Author
-
Melissa Alsina, Becker, Pamela S., Xiaobo Zhong, Adams, Alexia, Hari, Parameswaran, Rowley, Scott, Stadtmauer, Edward A., Vesole, David H., Logan, Brent, Weisdorf, Daniel, Qazilbash, Muzaffar, Popplewell, Leslie L., McClune, Brian, Bensinger, William, Riches, Marcie, Giralt, Sergio A., and Pasquini, Marcelo C.
- Subjects
- *
THALIDOMIDE , *HEMATOPOIETIC stem cell transplantation , *MULTIPLE myeloma treatment , *DISEASE progression , *GRAFT versus host disease , *MORTALITY , *HEMATOLOGY , *THERAPEUTICS - Abstract
Allogeneic hematopoietic cell transplantation (alloHCT) with reduced-intensity conditioning is an appealing option for patients with high-risk multiple myeloma (MM). However, progression after alloHCT remains a challenge. Maintenance therapy after alloHCT may offer additional disease control and allow time for a graft-versus-myeloma effect. The primary objective of this clinical trial was to determine the tolerability and safety profile of maintenance lenalidomide (LEN) given on days 1 to 21 of 28 days cycles, with intrapatient dose escalation during 12 months/cycles after alloHCT. Thirty alloHCT recipients (median age, 54 years) with high-risk MM were enrolled at 8 centers between 2009 and 2012. The median time from alloHCT to LEN initiation was 96 days (range, 66 to 171 days). Eleven patients (37%) completed maintenance and 10 mg daily was the most commonly delivered dose (44%). Most common reasons for discontinuation were acute graft-versus-host disease (GVHD) (37%) and disease progression (37%). Cumulative incidence of grades III to IV acute GVHD from time of initiation of LEN was 17%. Outcomes at 18 months after initiation of maintenance were MM progression, 28%; transplantation-related mortality, 11%; and progression-free and overall survival, 63% and 78%, respectively. The use of LEN after alloHCT is feasible at lower doses, although it is associated with a 38% incidence of acute GVHD. Survival outcomes observed in this high-risk MM population warrant further study of this approach. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
27. Adenovirus Viremia and Disease: Comparison of T Cell–Depleted and Conventional Hematopoietic Stem Cell Transplantation Recipients from a Single Institution
- Author
-
Lee, Yeon Joo, Chung, Dick, Xiao, Kun, Papadopoulos, Esperanza B., Barker, Juliet N., Small, Trudy N., Giralt, Sergio A., Zheng, Junting, Jakubowski, Ann A., and Papanicolaou, Genovefa A.
- Subjects
- *
ADENOVIRUS diseases , *VIREMIA , *HEMATOPOIETIC stem cell transplantation , *T cells , *HEALTH outcome assessment , *GRAFT versus host disease , *POLYMERASE chain reaction - Abstract
Abstract: Adenovirus (ADV) is an important cause of viral mortality in hematopoietic stem cell transplantation (HSCT). Recipients of T cell–depleted (TCD) HSCT are at increased risk for viral infections. We compared the rates and outcomes of ADV viremia and disease between TCD and conventional (CONV) HSCT at our institution. This was an observational study of 624 adult and pediatric recipients of myeloablative HSCT at Memorial Sloan-Kettering Cancer Center between January 1, 2006, and March 11, 2011. Viral cultures and ADV PCR were ordered as clinically indicated. ADV viremia by quantitative PCR assay was defined as 1 or more positive values ≥1,000 copies/mL or 2 or more consecutive positive values. Competing-risk regression analyses were used to identify predictors for ADV viremia. ADV viremia at 1 year after HSCT occurred in 8% of TCD HSCT recipients and in 4.0% of CONV HSCT recipients (P = .041). Among the TCD recipients, ADV viremia was seen in 15% of children, compared with 5% of adults (P = .008). Young age (hazard ratio [HR], 3.0; P < .001) and acute graft-versus-host disease (GVHD) (HR, 3.2; P = .001) were identified as risk factors for ADV viremia. ADV viremia was predictive of mortality (HR, 6.0; P < .001). ADV disease developed in 3.5% of TCD HSCT recipients and in 0.4% of CONV HSCT recipients (P = .022), with an attributable mortality of 27%. Among TCD HSCY recipients, grade II to IV GVHD was a risk factor for ADV disease (HR, 13; P < .001), but age was not. More than 90% of the cases of ADV disease involved a viral load of ≥10,000 copies/mL. Rates of ADV disease were 10-fold greater in TCD HSCT recipients compared with CONV HSCT recipients, predominantly in patients who developed acute GVHD. The benefit of preemptive therapy for an ADV viral load ≥10,000 copies/mL for preventing ADV disease in TCD HSCT recipients should be evaluated in prospective clinical trials. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
28. T Cell–Depleted Stem Cell Transplantation for Adults with High-Risk Acute Lymphoblastic Leukemia: Long-Term Survival for Patients in First Complete Remission with a Decreased Risk of Graft-versus-Host Disease
- Author
-
Goldberg, Jenna D., Linker, Alex, Kuk, Deborah, Ratan, Ravin, Jurcic, Joseph, Barker, Juliet N., Castro-Malaspina, Hugo, Giralt, Sergio, Hsu, Katharine, Jakubowski, Ann A., Jenq, Robert, Koehne, Guenther, Papadopoulos, Esperanza B., van den Brink, Marcel R.M., Young, James W., Boulad, Farid, Kernan, Nancy A., O’Reilly, Richard J., Prockop, Susan E., and Yahalom, Joachim
- Subjects
- *
T cells , *HEMATOPOIETIC stem cell transplantation , *LYMPHOBLASTIC leukemia , *LONG-term care facilities , *GRAFT versus host disease , *HOMOGRAFTS , *CONFIDENCE intervals , *PATIENTS , *CANCER risk factors ,DISEASES in adults - Abstract
Abstract: Consolidation with allogeneic hematopoietic stem cell transplantation (allo-HSCT) provides a survival benefit to patients with acute lymphoblastic leukemia (ALL). We have previously reported comparable survival and relapse rates after T cell–depleted (TCD) allo-HSCT compared with unmodified transplantations for acute myelogenous leukemia, myelodysplastic syndrome, and non-Hodgkin lymphoma with significantly decreased graft-versus-host disease (GVHD). We performed a 56-patient retrospective study to evaluate TCD allo-HSCT for the treatment of ALL after myeloablative total body irradiation–based therapy. The 2-year and 5-year overall survival rates for patients with ALL after TCD allo-HSCT were 0.39 (95% confidence interval [CI], 0.26-0.52) and 0.32 (95% CI, 0.19-0.44), respectively, and the 2-year and 5-year disease-free survival rates were 0.38 (95% CI, 0.25-0.50) and 0.32 (95% CI, 0.20-0.44). There was a trend toward improved survival of patients who underwent TCD allo-HSCT in first complete remission compared with those who did so in other remission states. The cumulative incidence of grade II-IV acute GVHD at 1 year was 0.20 (95% CI, 0.10-0.31), and no patients developed grade IV acute GVHD. The cumulative incidence of chronic GVHD in 41 evaluable patients at 2 and 5 years was 0.15 (95% CI, 0.04-0.26), and that of extensive chronic GVHD at 2 and 5 years was 0.05 (95% CI, 0-11.6). We demonstrate OS and DFS rates that compare favorably to unmodified allo-HSCT with lower rates of GVHD. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
29. Relapse after Allogeneic Hematopoietic Cell Therapy
- Author
-
van den Brink, Marcel R.M., Porter, David L., Giralt, Sergio, Lu, Sydney X., Jenq, Robert R., Hanash, Alan, and Bishop, Michael R.
- Subjects
- *
HEMATOPOIETIC stem cells , *STEM cell transplantation , *HOMOGRAFTS , *COMPLICATIONS from organ transplantation , *GRAFT versus host disease , *LEUKEMIA , *CANCER chemotherapy , *DISEASE relapse - Abstract
Disease relapse remains a major cause of mortality following allogeneic hematopoietic cell transplantation (HCT). Over the past decade, our understanding of the biology underlying the graft-versus-tumor/leukemia (GVT) effect has increased greatly; however, several other factors affect the occurrence and outcome of relapse, including conditioning regimen, type of allograft, and the histology, status, and sensitivity to chemotherapy of the disease being treated. The mainstay of relapse treatment is donor lymphocyte infusion (DLI), but the efficacy of DLI is quite variable depending on disease histology and state. As such, there is a significant need for novel therapies and strategies for relapse following allogeneic HCT, particularly in patients for whom DLI is not an option. The National Cancer Institute is sponsoring an international workshop to address issues and research questions relative to the biology, natural history, prevention, and treatment of relapse following allogeneic HCT. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
30. Symptoms and Quality of Life in Diverse Patients Undergoing Hematopoietic Stem Cell Transplantation
- Author
-
Cohen, Marlene Z., Rozmus, Cathy L., Mendoza, Tito R., Padhye, Nikhil S., Neumann, Joyce, Gning, Ibrahima, Aleman, Ana, Giralt, Sergio, and Cleeland, Charles S.
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *SYMPTOMS , *QUALITY of life , *DISEASE prevalence , *CANCER patients , *GRAFT versus host disease - Abstract
Context: Symptoms and quality of life (QOL) are critically important in hematopoietic stem cell transplantation (HSCT). However, few studies have examined these factors by transplant type among diverse cultures.Objectives: To identify and compare QOL and symptom severity and prevalence by transplant type in a diverse population having HSCT.Methods: The M. D. Anderson Symptom Inventory Blood and Marrow Transplantation (MDASI-BMT) module measured symptom severity and its impact. The Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) measured QOL.Results: Symptom data were collected from 164 patients at eight points (pretransplant to 100 days post-transplant) and QOL data at four times. Over time, symptom severity was significantly correlated with QOL and patients who had allogeneic transplants with myeloablative regimens showed more severe sleep disturbance and poorer QOL than patients having autologous transplants. Male patients reported less fatigue than female patients. However, ethnicity was not significant. Patients whose functional status was good had fewer of the five worst symptoms and higher QOL than patients with a poor functional status. Patients with acute graft-versus-host disease had more severe symptoms than those who did not.Conclusion: Type of transplant and preparative regimen are the most important aspects to consider when managing symptoms and QOL. This information is important for providing anticipatory guidance and support needed during the transplantation experience, to explore in future research the mechanisms involved in symptoms after HSCT, and to develop additional effective interventions. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
31. Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact of Tyrosine Kinase Inhibitors on Treatment Outcomes
- Author
-
Kebriaei, Partow, Saliba, Rima, Rondon, Gabriela, Chiattone, Alexandre, Luthra, Rajyalakshmi, Anderlini, Paolo, Andersson, Borje, Shpall, Elizabeth, Popat, Uday, Jones, Roy, Worth, Laura, Ravandi, Farhad, Thomas, Deborah, O’Brien, Susan, Kantarjian, Hagop, de Lima, Marcos, Giralt, Sergio, and Champlin, Richard
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *LYMPHOBLASTIC leukemia treatment , *PROTEIN-tyrosine kinase inhibitors , *CORD blood , *GRAFT versus host disease , *MORTALITY , *TREATMENT effectiveness - Abstract
The introduction of tyrosine kinase inhibitors (TKI) has revolutionized therapy for patients with acute lymphoblastic leukemia (ALL) who have the Philadelphia (Ph) chromosome. A retrospective analysis was conducted on 102 adults and 11 children who received a first-matched related (n = 60), matched unrelated (n = 40), mismatched cord blood (n = 12), or haploidentical (n = 1) allogeneic hematopoietic stem cell transplantation (HSCT) for Ph-positive (Ph+) ALL in first complete remission (n = 71), second complete remission (n = 11), or with active disease (n = 31) between 1990 and 2009. Sixty-seven patients received TKI with upfront ALL therapy, and 32 patients received TKI maintenance following HSCT. With median follow-up of 5 years among survivors (range: 1.1-20.4 years), overall survival (OS) was significantly better for patients transplanted in first remission compared with HSCT in advanced disease: 43% versus 16%, P = .002. Disease stage and age at time of HSCT, the development of acute graft-versus-host disease (aGVHD), and decade of HSCT were found to significantly impact OS, progression-free survival (PFS), and nonrelapse mortality (NRM) in multivariate analyses. Allogeneic HSCT provides durable remission for patients with Ph+ ALL in first remission. Neither TKI use pre- nor post-HSCT were found to significantly impact transplant outcomes in univariate and multivariate analyses. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
32. National Cancer Institute’s First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Summary and Recommendations from the Organizing Committee
- Author
-
Bishop, Michael R., Alyea, Edwin P., Cairo, Mitchell S., Falkenburg, J. H. Frederik, June, Carl H., Kröger, Nicolaus, Little, Richard F., Miller, Jeffrey S., Pavletic, Steven Z., Porter, David L., Riddell, Stanley R., van Besien, Koen, Wayne, Alan S., Weisdorf, Daniel J., Wu, Roy S., and Giralt, Sergio
- Subjects
- *
STEM cell transplantation , *HEMATOPOIETIC stem cells , *HOMOGRAFTS , *GRAFT versus host disease , *MEDICAL research , *LYMPHOCYTES , *CONFERENCES & conventions - Abstract
The National Cancer Institute’s First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation was organized and convened to identify, prioritize, and coordinate future research activities related to relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Each of the Workshop’s 6 Working Committees has published individual reports of ongoing basic, translational, and clinical research and recommended areas for future research related to the areas of relapse biology, epidemiology, prevention, and treatment. This document summarizes each committee’s recommendations and suggests 3 major initiatives for a coordinated research effort to address the problem of relapse after allo-HSCT: (1) to establish multicenter correlative and clinical trial networks for basic/translational, epidemiologic, and clinical research; (2) to establish a network of biorepositories for the collection of samples before and after allo-HSCT to aid in laboratory and clinical studies; and (3) to further refine, implement, and study the Workshop-proposed definitions for disease-specific response and relapse and recommendations for monitoring of minimal residual disease. These recommendations, in coordination with ongoing research initiatives and transplantation organizations, provide a research framework to rapidly and efficiently address the significant problem of relapse after allo-HSCT. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
33. Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma
- Author
-
Efebera, Yvonne A., Qureshi, Sofia R., Cole, Suzanne M., Saliba, Rima, Pelosini, Matteo, Patel, Ronak M., Koca, Ebru, Mendoza, Floralyn L., Wang, Michael, Shah, Jatin, Alousi, Amin, Hosing, Chitra, Popat, Uday, Kebriaei, Partow, Anderlini, Paolo, Khouri, Issa F., Champlin, Richard, Giralt, Sergio, and Qazilbash, Muzaffar H.
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *MULTIPLE myeloma diagnosis , *DISEASE relapse , *MEDICAL care , *HEALTH outcome assessment , *DISEASE remission , *GRAFT versus host disease , *FOLLOW-up studies (Medicine) - Abstract
Despite recent advances, multiple myeloma (MM) remains incurable, and most patients eventually develop progressive disease. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers a potentially curative option in 10%-20% of patients with relapsed or refractory disease. We evaluated the outcome of patients undergoing allo-HSCT with reduced-intensity conditioning (RIC) for relapsed and/or refractory MM at our institution. The study cohort included 51 patients with heavily pretreated, relapsed MM who underwent RIC allo-HSCT between 1996 and 2006. The median time from diagnosis to allo-HSCT was 34 months, and median follow-up in surviving patients was 27 months (range, 3-98 months). Cumulative transplantation-related mortality at 1 year was 25%. Progression-free survival (PFS) and overall survival (OS) at 2 years were 19% and 32%, respectively. The incidences of grade II-IV acute and chronic graft-versus-host disease were 27% and 47%, respectively. At the time of this analysis, 12 patients (24%) were alive, 7 of whom (14%) were in remission for up to 6 years after allo-HSCT. A lower β2 microglobulin level (<3.3) and previous autologous HSCT were predictive of lower nonrelapse mortality and longer PFS and OS. Our findings indicate that allo-HSCT with RIC is associated with acceptable toxicity and durable remission and survival in relapsed or refractory MM. The use of RIC allo-HSCT earlier in the course of the disease may offer the greatest benefit. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
34. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation
- Author
-
Pavletic, Steven Z., Kumar, Shaji, Mohty, Mohamad, de Lima, Marcos, Foran, James M., Pasquini, Marcelo, Zhang, Mei-Jie, Giralt, Sergio, Bishop, Michael R., and Weisdorf, Daniel
- Subjects
- *
GRAFT versus host disease , *HEMATOLOGICAL oncology , *HEMATOPOIETIC stem cells , *STEM cell transplantation , *CANCER treatment , *TREATMENT effectiveness , *HEALTH outcome assessment , *BIOMARKERS - Abstract
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is increasingly being used for treatment of hematologic malignancies, and the immunologic graft-versus-tumor effect (GVT) provides its therapeutic effectiveness. Disease relapse remains a cause of treatment failure in a significant proportion of patients undergoing alloHSCT without improvements over the last 2-3 decades. We summarize here current data and outline future research regarding the epidemiology, risk factors, and outcomes of relapse after alloHSCT. Although some factors (eg, disease status at alloHSCT or graft-versus-host disease [GVHD] effects) are common, other disease-specific factors may be unique. The impact of reduced-intensity regimens on relapse and survival still need to be assessed using contemporary supportive care and comparable patient populations. The outcome of patients relapsing after an alloHSCT generally remains poor even though interventions including donor leukocyte infusions can benefit some patients. Trials examining targeted therapies along with improved safety of alloHSCT may result in improved outcomes, yet selection bias necessitates prospective assessment to gauge the real contribution of any new therapies. Ongoing chronic GVHD (cGVHD) or other residual post-alloHSCT morbidities may limit the applicability of new therapies. Developing strategies to promptly identify patients as alloHSCT candidates, while malignancy is in a more treatable stage, could decrease relapses rates after alloHSCT. Better understanding and monitoring of minimal residual disease posttransplant could lead to novel preemptive treatments of relapse. Analyses of larger cohorts through multicenter collaborations or registries remain essential to probe questions not amenable to single center or prospective studies. Studies need to provide data with detail on disease status, prior treatments, biologic markers, and posttransplant events. Stringent statistical methods to study relapse remain an important area of research. The opportunities for improvement in prevention and management of post-alloHSCT relapse are apparent, but clinical discipline in their careful study remains important. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
35. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biological Considerations of Hematological Relapse following Allogeneic Stem Cell Transplantation Unrelated to Graft-versus-Tumor Effects: State of the Science
- Author
-
Cairo, Mitchell S., Jordan, Craig T., Maley, Carlo C., Chao, Clifford, Melnick, Ari, Armstrong, Scott A., Shlomchik, Warren, Molldrem, Jeff, Ferrone, Soldano, Mackall, Crystal, Zitvogel, Laurence, Bishop, Michael R., Giralt, Sergio A., and June, Carl H.
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *GRAFT versus host disease , *DRUG resistance , *STEM cell transplantation ,DISEASE relapse prevention - Abstract
Hematopoietic malignant relapse still remains the major cause of death following allogeneic hematopoietic stem cell transplantation (HSCT). Although there has been a large focus on the immunologic mechanisms responsible for the graft-versus-tumor (GVT) effect or lack thereof, there has been little attention paid to investigating the biologic basis of hematologic malignant disease relapse following allogeneic HSCT. There are a large number of factors that are responsible for the biologic resistance of hematopoietic tumors following allogeneic HSCT. We have focused on 5 major areas including clonal evolution of cancer drug resistance, cancer radiation resistance, genomic basis of leukemia resistance, cancer epigenetics, and resistant leukemia stem cells. We recommend increased funding to pursue 3 broad areas that will significantly enhance our understanding of the biologic basis of malignant relapse after allogeneic HSCT, including: (1) genomic and epigenetic alterations, (2) cancer stem cell biology, and (3) clonal cancer drug and radiation resistance. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
36. NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction
- Author
-
Miller, Jeffrey S., Warren, Edus H., van den Brink, Marcel R.M., Ritz, Jerome, Shlomchik, Warren D., Murphy, William J., Barrett, A. John, Kolb, Hans Jochem, Giralt, Sergio, Bishop, Michael R., Blazar, Bruce R., and Falkenburg, J.H. Frederik
- Subjects
- *
TRANSPLANTATION of organs, tissues, etc. , *HEMATOPOIETIC stem cells , *HOMOGRAFTS , *STEM cell transplantation , *COMPLICATIONS from organ transplantation , *CANCER relapse , *GRAFT versus host disease , *CONFERENCES & conventions - Abstract
The success of allogeneic hematopoietic stem cell transplantation (HSCT) depends on the infusion of benign stem cells as well as lymphocytes capable of participating in a graft-versus-tumor/leukemia (GVL) reaction. Clinical proof of concept is derived from studies showing increased relapse after the infusion of lymphocyte depleted hematopoietic grafts as well as the therapeutic efficacy of donor lymphocyte infusions without chemotherapy to treat relapse in some diseases. Despite this knowledge, relapse after allogeneic HSCT is common with rates approaching 40% in those with high-risk disease. In this review, we cover the basic biology and potential application to exploit adaptive T cell responses, minor histocompatibility antigens, contraction and suppression mechanisms that hinder immune responses, adaptive B cell responses and innate NK cell responses, all orchestrated in a GVL reaction. Optimal strategies to precisely balance immune responses to favor GVL without harmful graft-versus-host disease (GVHD) are needed to protect against relapse, treat persistent disease and improve disease-free survival after HSCT. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
37. A Phase III Study of Infliximab and Corticosteroids for the Initial Treatment of Acute Graft-versus-Host Disease
- Author
-
Couriel, Daniel R., Saliba, Rima, de Lima, Marcos, Giralt, Sergio, Andersson, Borje, Khouri, Issa, Hosing, Chitra, Ippoliti, Cindy, Shpall, Elizabeth J., Champlin, Richard, and Alousi, Amin
- Subjects
- *
INFLIXIMAB , *GRAFT versus host disease , *DRUG efficacy , *CORTICOSTEROIDS , *HORMONE therapy , *COMPARATIVE studies , *BONE marrow transplantation , *TUMOR necrosis factors , *CLINICAL trials , *THERAPEUTICS - Abstract
Anti-Tumor Necrosis Factor Alpha (TNF-α) therapy with infliximab has shown to be effective for patients with steroid-refractory acute graft-versus-host disease (aGVHD). An open-labeled, phase III trial was conducted to determine if the addition of infliximab to steroids could improve results for patients with newly diagnosed grade II-IV aGVHD. A total of 63 patients were randomized either to 2 mg/kg/day methylprednisolone (MP) or infliximab+ MP. Average age was 47 years (range: 20-70 years); 64% were male. Fifty-three percent and 51% of patients received a matched-sibling and/or bone marrow (BM) graft. Sixty-seven percent had grade II, 33% grade III-IV aGVHD; 62% had skin, 53% gastrointestinal (GI), and 7% had liver involvement. At days 7 and 28, the response rate for infliximab+ MP versus MP was 52% versus 78%, P=.03 and 62% versus 58%, P=.7, respectively. Cumulative incidences of GVHD-related mortality, nonrelapse mortality (NRM), and overall survival (OS) were not significantly different between the 2 groups (GVHD-related mortality: 38% versus 32%, P=.6; NRM: 52% versus 36%, P=.3; OS: 17% and 28%, P=.4 for infliximab+ MP versus MP, respectively). Patients with newly diagnosed aGVHD derive no benefit from the addition of anti-TNF-α therapy with infliximab when compared to corticosteroids alone. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
38. Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes
- Author
-
Besien, Koen Van, Kunavakkam, Rangesh, Rondon, Gaby, De Lima, Marcos, Artz, Andrew, Oran, Betul, and Giralt, Sergio
- Subjects
- *
FLUDARABINE , *MONOCLONAL antibodies , *GRAFT versus host disease , *HOMOGRAFTS , *LEUKEMIA treatment , *MYELOID leukemia , *HEALTH outcome assessment , *THERAPEUTICS - Abstract
Abstract: The purpose of this study was to determine the effect of alemtuzumab on treatment-related mortality (TRM), relapse, overall survival (OS), and disease-free survival (DSF) in patients with acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS) undergoing reduced intensity conditioning (RIC). We compared the outcome of 95 patients treated at the University of Chicago with fludarabine melphalan (Flu + Mel) + alemtuzumab conditioning and 59 patients treated at the M.D. Anderson Cancer Center with Flu + Mel conditioning. Both groups had similar patient and donor characteristics. There were no significant differences in TRM, relapse, survival, and DFS between the 2 groups. The incidence of acute graft-versus-host disease (aGVHD) grade II-IV (relative risk [RR] 5.5, P < .01) and chronic GVHD (cGVHD) (RR 6.6, P < .01) were significantly lower in patients receiving alemtuzumab. The addition of alemtuzumab to an RIC regimen dramatically reduces the incidence of aGVHD and cGVHD in patients with AML and MDS undergoing allogeneic transplantation. TRM, relapse risk, OS and DFS are not affected. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
39. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007
- Author
-
Ferrara, James L.M., Anasetti, Claudio, Stadtmauer, Edward, Antin, Joseph, Wingard, John, Lee, Stephanie, Levine, John, Schultz, Kirk, Appelbaum, Frederick, Negrin, Robert, Giralt, Sergio, Bredeson, Christopher, Heslop, Helen, and Horowitz, Mary
- Subjects
- *
MEDICAL research , *CONFERENCES & conventions , *MEDICAL experimentation on humans , *CELLULAR therapy - Abstract
Abstract: Outcomes of hematopoietic cell transplantation are steadily improving. New techniques have reduced transplant toxicities, and there are new sources of hematopoietic stem cells from unrelated donors. In June 2007 the Blood and Marrow Transplant Clinical Trials Network convened a State of the Science Symposium of more than 200 participants in Ann Arbor to identify the most compelling clinical research opportunities in the field. This report summarizes the symposium’s discussions and identifies eleven high priority clinical trials that the network plans to pursue over the course of the next several years. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
40. Transplant-Associated Microangiopathy in Patients Receiving Tacrolimus Following Allogeneic Stem Cell Transplantation: Risk Factors and Response to Treatment
- Author
-
Oran, Betul, Donato, Michele, Aleman, Ana, Hosing, Chitra, Korbling, Martin, Detry, Michelle A., Wei, Caimiao, Anderlini, Paolo, Popat, Uday, Shpall, Elizabeth, Giralt, Sergio, and Champlin, Richard E.
- Subjects
- *
GRAFT versus host disease , *STEM cell transplantation , *TACROLIMUS , *THERAPEUTICS - Abstract
Abstract: Transplant-associated microangiopathy (TAM) is a life-threatening complication after allogeneic HSCT, particularly with the use of calcineurin inhibitors as post-transplantation immunosuppressive therapy. We report our experience with TAM after HSCT with tacrolimus-based GVHD prophylaxis in a single-center study. Sixty-six of 1219 transplant recipients developed TAM with a cumulative incidence of 5.9%. Risk factors for TAM were female gender, lymphoid malignancy, receipt of a matched unrelated donor, and grade II-IV aGVHD. Most patients had infection and/or active GVHD at the diagnosis of TAM (82%). In the absence of renal dysfunction or encephalopathy, tacrolimus was generally continued, maintaining blood levels within the lower therapeutic range. Sixty-three patients were treated with plasma exchange. The cumulative incidence of response of TAM was 60%. Only 1 patient had a response of TAM without resolution of concomitant infections or GVHD. Six-month survivals were 0% and 50% for TAM nonresponders and responders, respectively. In conclusion, TAM is a common, life-threatening complication of allogeneic hematopoietic transplantation using tacrolimus prophylaxis. Control of TAM generally requires response of associated infections and GVHD. TMA response may occur despite continuation of tacrolimus treatment. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
41. Pre-Transplant and Peri-d100 Gastrointestinal Dysbiosis Is Associated with the Subsequent Development of Chronic Graft-Versus-Host Disease.
- Author
-
Markey, Kate Ann, Gomes, Antonio, Littmann, Eric, Devlin, Sean M., Slingerland, Ann E., Moore, Gillian, Fatmi, Samira, Slingerland, John, Clurman, Annelie, Maloy, Molly A., Pamer, Eric G., Taur, Ying, Giralt, Sergio A., Perales, Miguel-Angel, Ponce, Doris M., Peled, Jonathan U., and van den Brink, Marcel R.M.
- Subjects
- *
GRAFT versus host disease , *GASTROINTESTINAL diseases , *GUT microbiome , *MICROBIAL communities , *CLINICAL trials - Abstract
Chronic GVHD affects ∼50% of long-term survivors of allo-HCT, and is the leading cause of mortality in patients who survive to two years. Unlike aGVHD, cGVHD pathology is fibrotic and shares features with the autoimmune conditions Sjogrens syndrome and systemic sclerosis. Gastrointestinal microbiota signatures have been associated with these conditions, and we thus hypothesized that the configuration of microbial communities would also be associated with cGVHD, and may serve as predictive biomarkers or offer mechanistic insights into cGVHD pathogenesis. We identified a cohort of 55 cGVHD patients, confirmed by formal clinical consensus (NIH criteria), transplanted at MSKCC from 2013-2017. The majority received unmodified PBSC (60%) with the remainder receiving CD34-selected (20%), and marrow or cord-blood grafts (20%). 532 stool samples from 55 cGVHD cases were compared with 1462 samples from 165 controls (matched for graft source). Median cGVHD onset was d194. Patient characteristics in the cases and controls were equivalent, including rate of aGVHD prior to day 100 (55% vs 46%; p = 0.27). In addition, we compared the cGVHD cases with an independent cohort of patients with Gr3-4 aGVHD (n = 71 patients, contributing 835 samples), and an additional control group (matched for graft-source, n = 213 patients, 1786 samples) who remained GVHD-free. All stool samples underwent 16S-targeted sequencing on the Illumina platform. In addition, available peri-d100 samples underwent shotgun metagenomic sequencing (cGVHD, n = 9; controls, n = 25). There were no differences in a-diversity as a function of time peri-HCT, nor did we observe clustering of community characteristics in tSNE-space, or differences using the linear discriminant effect size (LEfSE) pipeline when we specifically examined samples collected pre-transplant, peri-engraftment, or peri-d100. In contrast, a set of genera reported to be enriched in intestinal communities of patients with autoimmune diseases were selected for targeted analysis and revealed higher relative abundance in Prevotella prior to HCT in cGVHD cases (case vs source-matched control p < 0.0001; Fig 1A). When we analyzed the genera known to be relevant in GVHD, we found increased relative abundance of Akkermansia and Streptococcus at day 100 in the cGVHD cases compared to controls (p = 0.017; Fig 1B). LEfSE analysis of shotgun metagenomic sequences at d100 revealed higher abundance of members of class Actinobacteria , as well as Bifidobacterium longum in the control cases compared to the patients who went on to develop cGVHD. Here, we report for the first time, intestinal microbial signatures that are associated with cGVHD and are identifiable pre-HCT and peri-d100. The cGVHD-associated dysbiosis we have identified may have value as both a biomarker for cGVHD risk and mechanistic relevance. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
42. Photobiomodulation (PBM) Provides a Prompt and Near-Resolution Response to Advanced Oral Chronic Graft-Versus-Host Disease (cGVHD) after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT).
- Author
-
Ponce, Doris M., Markova, Alina, Moore, Gillian, Dahi, Parastoo B, Papadopoulos, Esperanza B., Tamari, Roni, Giralt, Sergio A., Prockop, Susan E, and Barash, Andrei
- Subjects
- *
GRAFT versus host disease , *HEMATOPOIETIC stem cell transplantation , *PHOTOTHERAPY , *TRANSFORMING growth factors , *IMMUNOSUPPRESSIVE agents , *ADRENOCORTICAL hormones - Abstract
Background cGVHD is a major complication after allo-HSCT. The oral cavity is frequently affected and may present with painful ulcerations, intraoral discomfort, and limitation to oral intake. While systemic corticosteroids remain first line therapy for moderate/ severe cGVHD, topical and intralesional immunosuppressant (IS)-based therapies have been used with modest effect. PBM, a non-invasive light therapy, appears to promote tissue recovery via direct absorption of cytochrome C oxidase and activation of TGF-β1, and has been used for the prevention and treatment of radiation-induced mucositis in head & neck cancer. However, the effect of PBM therapy in oral cGVHD is currently unknown. Methods We evaluated 7 patients (median age 47) who underwent allo-HSCT (7 PBSC grafts) after myeloablative (n = 3) and reduced (n = 4) conditioning between 09/2015-05/2017. Patients developed moderate (n = 2) or severe (n = 5) oral cGVHD and received PBM (2x/week for 3 weeks) after failure to improve with topical corticosteroid and/or topical tacrolimus therapy +/- intralesional triamcinolone injections and systemic IS. Thor® laser LX2 with wavelengths of 660 nm (visible-red) and 810 nm (near-infrared) was applied extra-orally. The psychometric questionnaire for pain rating (Visual Analogue Scale [VAS], scale 0-10), and oral GVHD (OGVHD) score (severity of erythema, lichenoid changes, ulcers and mucoceles, scale 0-15) were used weekly for the assessment of therapeutic response. Results The baseline oral cGVHD evaluation revealed high VAS (median 7, range 3-8) and OGVHD (median 9, range 6-9) scores. Patients had affected oral cavity that included lichen planus-like changes, ulcers, mucositis, gingivitis, and/or erythema (Fig. 1A-B). The first therapeutic response assessment was obtained 1 week after initiation of therapy and showed improvement in pain by VAS score (median 3). Subsequent assessments were obtained for the duration of PBM therapy and showed overall improvement in the pain scale and healing of the oral cavity (Fig. 1C-D, 2A-B). At the end of treatment, the median VAS score was 2 (range 1-2) and OGVHD was 3 (range 1-4). Treatment was well tolerated, and all patients received the intended number of PBM treatments in the planned period of 3 weeks. No adverse events were reported as related to PBM. Conclusions Advanced oral cGVHD achieved near-complete resolution of pain and oral cavity lesions after PBM therapy. Notable, patients who previously failed to respond to upfront topical and systemic IS treatment achieved high therapeutic response with PBM. Improvement in pain scale was observed 1 week after starting therapy and healing of the oral cavity was observed at 2 weeks. This non-IS treatment appears feasible, safe and promising in oral cGVHD. A prospective study is needed to confirm these preliminary findings. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
43. HLA-a*0101 Allele Is Associated with Increased Risk of Cutaneous Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
- Author
-
Fonseca, Maira, Jakubowski, Ann A., Devlin, Sean M., Young, James W., Fatmi, Samira, Maloy, Molly A., Giralt, Sergio A., Ponce, Doris M., and Markova, Alina
- Subjects
- *
GRAFT versus host disease , *HLA histocompatibility antigens , *ALLELES , *INTERLEUKIN-2 , *HEMATOPOIETIC stem cell transplantation , *CORD blood transplantation - Abstract
Introduction Acute graft-versus-host disease (aGVHD) remains a substantial cause of morbidity and mortality after unmodified and ex-vivo CD34+ selected/T-cell depleted (TCD) allogeneic hematopoietic stem cell transplantation (alloHSCT). We identified a cluster of patients who developed severe cutaneous aGVHD and expressed MHC class I HLA-A*0101. Objective To investigate if HLA-A*0101 expression correlates with an increased risk of severe cutaneous aGVHD after alloHSCT. Methods We evaluated 831 patients who received unmodified or TCD allograft at a single institution between 03/2010 and 02/2017. Patients who received cord blood transplants or <8/8 HLA-matched grafts were excluded. For patients with cutaneous aGVHD, we assessed donor-recipient HLA-typing, time of onset, grade at onset, and highest overall grade of cutaneous aGVHD. Results HLA-A*0101 was expressed in 206 (25%) patients (98 TCD, 108 unmodified). These patients had similar demographics to those lacking HLA-A*0101 (Table). At day 180, patients expressing HLA-A*0101 had higher incidence of grade III-IV cutaneous aGVHD compared with patients lacking HLA-A*0101 expression in both the TCD (8% vs. 3%, p =0.027) and unmodified (11% vs. 4%, p =0.01) cohorts (Fig 1). In a multivariate cause-specific Cox model, the presence of HLA-A*0101 in the TCD alloHSCT cohort correlated with increased risk of grade III-IV cutaneous aGVHD [HR=2.79 (95% CI: 1.07-7.28), p =0.036] after adjusting for related status of donor. In the unmodified alloHSCT cohort, presence of HLA-A*0101 allele correlated with increased risk of grade III-IV cutaneous aGVHD [HR=2.68 (95% CI: 1.24-5.79), p = 0.012)] after adjusting for myeloablative v non-myeloablative conditioning and donor relationship status. There were no statistically significant differences in OS or TRM between HLA-A*0101 expressing vs non-expressing patients in the cohorts. Conclusions In this group, donor/recipient expression of HLA-A*0101 correlated with an increased incidence and severity of cutaneous aGVHD after TCD and unmodified alloHSCT. If confirmed in a larger cohort, these findings have potential practical implications in the development of prophylaxis or early therapeutic strategies targeting the skin in this high-risk population. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
44. Multicenter Microbiota Analysis Indicates That Pre-HCT Microbiota Injury Is Prevalent across Geography and Predicts Poor Overall Survival.
- Author
-
Peled, Jonathan U., Gomes, Antonio, Stein-Thoeringer, Christoph, Slingerland, John, Slingerland, Ann E., Weber, Daniela, Markey, Kate Ann, Smith, Melody, Ponce, Doris M., Clurman, Annelie, Sung, Anthony D., Hashimoto, Daigo, Maloy, Molly A., Khan, Niloufer, Gyurkocza, Boglarka, Giralt, Sergio A., Perales, Miguel-Angel, Jenq, Robert R., Taur, Ying, and Xavier, Joao
- Subjects
- *
GRAFT versus host disease , *DISEASE prevalence , *IMMUNE reconstitution inflammatory syndrome , *ENTEROTYPES , *ANTIBIOTICS - Abstract
Intestinal microbiota composition is associated with important allo-HCT outcomes including relapse, GVHD, immune reconstitution, and infections. Intestinal diversity assessed peri-neutrophil-engraftment is predictive of TRM and overall survival. These observations were made in single-center studies of post-HCT stool samples. We hypothesized that the pre-HCT microbiota is also a determinant of post-HCT outcomes. 1,922 stool samples were collected ∼weekly from 991 allo-HCT pts at 4 centers (Cohorts 1 and 2 in the US; cohort 3 in Europe; cohort 4 in Japan). The patients varied in diagnosis, graft sources, and conditioning intensity. All samples were 16S sequenced and analyzed at a central lab. Pre-HCT a-diversity (inverse Simpson) values in 4 cohorts were 1.7-to-2.5-fold lower than those of healthy volunteers (A , p<0.005). In addition, while the intestinal compositions of most healthy volunteers could be matched to the Enterotypes classifier of healthy gut communities, pre-HCT samples from all 4 centers had configurations poorly characterized by this independent classification scheme (B). Thus, post-HCT microbiota injuries are preceded by community structures that are already abnormal pre-HCT, consistent with our prior observation that pre-HCT antibiotic exposure is a risk factor for poor outcomes. We next asked how similar these pre-HCT communities are across geography. Bray-Curtis distances between cohorts were much smaller than the changes observed over time during transplantation (C , p<0.005). In the largest cohort, pts in the lowest pre-HCT diversity quartile had a lower overall survival than pts in the highest quartile (D , p<0.009). To better characterize these low-diversity phenotypes, we defined domination as a microbiota injury in which any taxon comprised >30% of bacterial abundance. The dominating taxa belonged to multiple genera, most commonly Enterococcus (E). In all 4 cohorts, the cumulative incidence of monodomination was >50% by d+0 and >87% by d+28 (Fig F). In the largest cohort, low-diversity states were associated with exposure to broad-spectrum antibiotics, conditioning intensity, and low calorie intake. In conclusion, we demonstrate that allo-HCT pts from 4 institutions on 3 continents presented with pre-HCT microbiota configurations that were similar to one another and distinct from those of healthy individuals. Severe microbiota injury as revealed by domination is a common event that begins before allograft infusion, and pre-HCT microbiota injury predicts poor overall survival. These observations suggest the pre-HCT period as a window of opportunity to (a) assess microbiota injury as part of comorbidity evaluation, (b) inform selection of antibiotic prophylaxis, gut-decontamination, GVHD-prophylaxis, or conditioning regimens, and (c) intervene with microbiota injury-remediation or prevention strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
45. Lack of a Significant Pharmacokinetic Interaction between Letermovir and Calcineurin Inhibitors in Allogeneic HCT Recipients.
- Author
-
Maples, Kathryn T., Maloy, Molly A., Lin, Andrew, DeRespiris, Lauren, Griffin, Meagan, Lau, Carmen, Proli, Anthony J., Papanicolaou, Genovefa A., Seo, Susan K., Barker, Juliet N., Perales, Miguel-Angel, Giralt, Sergio A., and Bhatt, Valkal
- Subjects
- *
ANTIVIRAL agents , *CALCINEURIN , *HEMATOPOIETIC stem cell transplantation , *CYTOMEGALOVIRUS disease treatment , *CORD blood transplantation , *GRAFT versus host disease - Abstract
Background Letermovir (LET) is approved for the prophylaxis of cytomegalovirus (CMV) in allogeneic hematopoietic cell transplantation (allo-HCT) patients. LET is a weak-moderate CYP3A4 inhibitor, which may impact calcineurin inhibitor (CNI) levels. In the phase 1 trial, LET caused an increase in maximum plasma concentrations (C max) of CSA and tacrolimus by 37% and 70%, respectively. There are no data to correlate how the C max increase in the presence of LET may affect CNI trough levels. Methods A retrospective review was conducted to evaluate the effect of LET on CNI trough levels and determine if empiric dose adjustments are needed. Patients ≥ 18 years were included if they received an allo-HCT with a CNI from February to June 2018 and received LET 480 mg daily or 240mg daily for tacrolimus- or CSA-based GVHD prophylaxis, respectively. The primary endpoint was percent change in concentration to dose (C/D) ratio over the 7-day period after initiation of LET. The C/D ratio allows for an analysis of the effect on trough levels at any given dose, which we would expect to rise upon initiation of LET due to CYP inhibition. LET reaches steady state in 36-60 hours; therefore, C/D percent changes were evaluated both from baseline to 4 days post-LET and from day 4 to day 7. Results Thirty-four patients (median age 53, range 24-75) were included in the analysis, with 24 (70.6%) patients receiving a tacrolimus-based graft-versus-host disease (GVHD) prophylaxis and 10 (29.4%) patients receiving CSA-based GVHD prophylaxis. There were 8 (24%) umbilical cord blood transplants, 10 (29%) haploidentical HCTs, and 16 (47%) conventional HCTs, with 14 patients (41%) receiving myeloablative conditioning. LET was initiated on a median of day 7 (range 6-30) post-HCT, and 23 patients (68%) received the drug orally. In the 10 patients who received CSA, there was an average of 3.8 (range 1-6) dose changes over 7 days. From baseline to 4 days post-LET, the mean percent change in C/D ratio was +15.9%, with a subsequent -10.0% change in C/D ratio from day 4 to day 7. In the 24 patients who received tacrolimus, there was an average of 2.2 (range 0-5) dose changes over 7 days. From baseline to 4 days post-LET, the mean percent change in C/D ratio was +20.4%, with a subsequent -18.9% change in C/D ratio from day 4 to day 7. Days 0 to 7 trough levels for all patients are displayed in Figures 1 and 2. Conclusion An empiric dose reduction in CNIs upon initiation of LET does not appear to be warranted based on this pilot study. An increase in trough levels is seen within 4 days after initiation of LET; however, the increase seems marginal and is compensated for by adjusting doses based on levels, which is the standard of care. Larger studies are needed to assess additional factors that may affect this drug-drug interaction. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
46. 262 - Graft-Versus Host Disease (GVHD Status and Severity Mediate Late Effects of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in a 1-Year Landmark Analysis.
- Author
-
Sola, Maria, Devlin, Sean M., Maloy, Molly, Dierov, Djamilia, Barker, Juliet N., Castro-Malaspina, Hugo, Dahi, Parastoo, Jakubowski, Ann A., Koehne, Guenther, Papadopoulos, Esperanza B., Sauter, Craig S., Tamari, Roni, van den Brink, Marcel R.M., Young, James W., Giralt, Sergio A., Perales, Miguel-Angel, and Ponce, Doris M.
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *GRAFT versus host disease , *HEMATOLOGIC malignancies , *MYELOSUPPRESSION , *COMPARATIVE studies , *MEDICAL informatics , *THERAPEUTICS - Published
- 2017
- Full Text
- View/download PDF
47. Double Unit Cord Blood Transplantation (dCBT) Progression-Free Survival (PFS) is Unaffected by Grade III-IV Acute Graft-Versus-Host Disease (aGVHD) and Survivors Are Likely to Discontinue Immunosuppression (IS) and Reconstitute T-Cells.
- Author
-
Politikos, Ioannis, Devlin, Sean M., Yoo, Yeon, Lauer, Emily, Ciolino, Cristi, Dierov, Djamilia, Herman, Dara, Mosesso, Kara, Nieves, Jimmy, Giralt, Sergio A., Perales, Miguel-Angel, Kernan, Nancy A., Scaradavou, Andromachi, Ponce, Doris M., and Barker, Juliet N.
- Subjects
- *
GRAFT versus host disease , *ACUTE diseases , *CORD blood , *PROGRESSION-free survival , *IMMUNOSUPPRESSION , *T cells - Published
- 2016
- Full Text
- View/download PDF
48. Long-Term Prognosis Among 1-Year Survivors of Ex Vivo T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation: A Landmark Analysis.
- Author
-
Cho, Christina, Hsu, Meier, Avecilla, Scott, Barba, Pere, Barker, Juliet N., Castro-Malaspina, Hugo, Devlin, Sean M., Giralt, Sergio A., Jakubowski, Ann A., Koehne, Guenther, Meagher, Richard, O'Reilly, Richard J., Papadopoulos, Esperanza, Ponce, Doris M., van den Brink, Marcel R.M., Young, James W., and Perales, Miguel-Angel
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *HOMOGRAFTS , *GRAFT versus host disease , *DISEASE relapse , *REGRESSION analysis , *COHORT analysis , *PROGNOSIS - Published
- 2016
- Full Text
- View/download PDF
49. Prospective Evaluation of Cord Blood (CB) and Haplo-Identical (Haplo) Donor Availability Reveals Compromised Donor Access for Both CB and Haplo Grafts in Minority Patients.
- Author
-
Kosuri, Satyajit, Wolff, Tara, Lauer, Emily, Byam, Courtney, Yoo, Yeon, Davis, Eric, Paulson, Jennifer, Sideroff, Melissa, Wells, Deborah S., Perales, Miguel-Angel, Scaradavou, Andromachi, Giralt, Sergio A., Ponce, Doris M., and Barker, Juliet N.
- Subjects
- *
CORD blood , *ORGAN donors , *GRAFT versus host disease , *MEDICAL care , *CLINICAL trials - Published
- 2016
- Full Text
- View/download PDF
50. CD34+ Selected Ex-Vivo T-Cell Depleted (TCD) Grafts for Allogeneic Hematopoietic Cell Transplantation (Allo-HSCT) Is Associated with Low Incidence of Acute and Chronic Graft-Versus-Host Disease (GVHD) and High Chronic-Gvhd/Relapse-Free Survival.
- Author
-
Barba, Pere, Hilden, Patrick, Devlin, Sean M., Maloy, Molly, Ciolino, Cristi, Dierov, Djamilia, Herman, Dara, Mosesso, Kara, Nieves, Jimmy, Barker, Juliet N., Castro-Malaspina, Hugo, Jakubowski, Ann A., Koehne, Guenther, Papadopoulos, Esperanza, Sauter, Craig S., van den Brink, Marcel R.M., Young, James W., Giralt, Sergio A., Perales, Miguel-Angel, and Ponce, Doris M.
- Subjects
- *
CD34 antigen , *T-cell receptor genes , *TRANSPLANTATION of organs, tissues, etc. , *HEMATOPOIETIC stem cells , *GRAFT versus host disease , *DISEASE relapse - Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.